|  reults for their MS drug.
Excerpt--"RPI-78M reduced the clinical symptoms by more than 80 percent," remarked neurologist Mitchell S. Felder, M.D. "There was also more than an 87 percent reduction in the number of EAE histopathologic lesions. If these results are duplicated in the human trials it could possibly revolutionize the treatment of MS. The results from an EAE model indicate that this drug may also have therapeutic potential for a great number of other neurologic conditions such as Acute Disseminated Encephalomyelitis, Transverse Myelitis, Krabbe's Leukodystrophy, Alexander's Disease, Canavan's Disease and Adrenoleukodystrophy," he concluded.
full article link at http://www.nutrapharma.com/investor/pr/10_14_04.htm
| |
